All lobbying filings

FEROX STRATEGIES

Lobbying for FRESENIUS KABI USA LLC · Generic and biosimilar pharmaceutical manufacturer

Filing Q3 report

Reporting period

3rd Quarter 2025

July 1 - Sep 30 · Posted Oct 20, 2025

Income

$50,000.00

What the client paid this registrant for the period.

Client based in

Illinois

Official filing document

Government bodies contacted 6

Commerce, Dept of (DOC)
Executive Office of the President (EOP)
Health & Human Services, Dept of (HHS)
HOUSE OF REPRESENTATIVES
SENATE
U.S. Trade Representative (USTR)

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 3

Health Issues

General healthcare issues related to generic and biosimilar industries.

Pharmacy

General patent issues related to generic and biosimilar industries.

Trade (domestic/foreign)

General issues related to trade.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.